Psoriasis treatment market projected to reach USD 54.40 billion by 2032 due to growth in biologic treatments.

From GlobeNewswire: 2025-03-12 09:00:00

The Psoriasis Treatment Market was valued at USD 22.38 billion in 2023 and is expected to reach USD 54.40 billion by 2032 with a CAGR of 10.4%. Biologic treatments have revolutionized psoriasis management, offering more effective and safer options. Major players include AbbVie, Amgen, Johnson & Johnson, Novartis, and Eli Lilly.

In 2023, Tumor Necrosis Factor (TNF) inhibitors led the psoriasis treatment market, while Interleukin (IL) inhibitors are projected to grow rapidly. Parenteral administration was dominant, but topical treatments are expected to grow quickly. Hospital pharmacies were key in 2023, but retail pharmacies are anticipated to see the highest growth.

North America dominated the psoriasis treatment market in 2023, with Asia-Pacific showing the highest growth potential. Recent developments include Amgen’s FDA approval for a biosimilar of Stelara and Lords Mark Biotech’s introduction of Tinefcon. Psoriasis affects 2-3% of the global population, with biologic treatments more common in North America and topical treatments in the Asia-Pacific region. The Psoriasis Treatment Market Analysis & Outlook for 2024-2032 is now available. Get all the details at SNS Insider for a comprehensive report on market trends and forecasts. Contact [email protected] for customized research options. SNS Insider is a global market research agency providing accurate data, consumer insights, and opinions to help clients make informed decisions in a changing market landscape.



Read more at GlobeNewswire: Psoriasis Treatment Market Size to Hit USD 54.40 Billion by